Cyclin-dependent kinase 5 acts as a critical determinant of AKT-dependent proliferation and regulates differential gene expression by the androgen receptor in prostate cancer cells

Molecular Biology of the Cell

Volumn 26, Issue 11, 2015, Pages 1971-1984

  Lindqvist, Julia ^a,b   Imanishi, Susumu Y ^b   Torvaldson, Elin ^a,b   Malinen, Marjo ^c   Remes, Mika ^a   Örn, Fanny ^a,b   Palvimo, Jorma J ^c   Eriksson, John E ^a,b  

^a ÅBO AKADEMI UNIVERSITY   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; CYCLIN DEPENDENT KINASE 5; PROTEIN KINASE B; ROSCOVITINE; SERINE; TRANSCRIPTION FACTOR; AR PROTEIN, HUMAN; CDK5 PROTEIN, HUMAN;

ARTICLE; CELL CYCLE; CELL CYCLE REGULATION; CELL FUNCTION; CELL GROWTH; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; GENE AMPLIFICATION; GENE EXPRESSION; GENE OVEREXPRESSION; GENE TARGETING; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; LNCAP CELL LINE; NULL CELL; PRIORITY JOURNAL; PROSTATE CANCER CELL LINE; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; PATHOPHYSIOLOGY; PHOSPHORYLATION; PROSTATE TUMOR;

CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE 5; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION;

EID: 84930389493     PISSN: 10591524     EISSN: 19394586     Source Type: Journal    
DOI: 10.1091/mbc.E14-12-1634     Document Type: Article

References (47)

1. Ayala G, Thompson T, Yang G, Frolov A, Li R, Scardino P, Ohori M, Wheeler T, Harper W (2004). High levels of phosphorylated form of Akt-1 in prostate cancer and non-neoplastic prostate tissues are strong predictors of biochemical recurrence. Clin Cancer Res 10, 6572-6578.
2. Berberich N, Uhl B, Joore J, Schmerwitz UK, Mayer BA, Reichel CA, Krombach F, Zahler S, Vollmar AM, Fürst R (2011). Roscovitine blocks leukocyte extravasation by inhibition of cyclin-dependent kinases 5 and 9. Br J Pharmacol 163, 1086-1098.
3. Chen M-C, Huang C-Y, Hsu S-L, Lin E, Ku C-T, Lin H, Chen C-M (2012a). Retinoic acid induces apoptosis of prostate cancer DU145 cells through Cdk5 overactivation. Evid Based Complement Alternat Med 2012, 580736.
4. Chen S, Gulla S, Cai C, Balk SP (2012b). Androgen receptor serine 81 phosphorylation mediates chromatin binding and transcriptional activation. J Biol Chem 287, 8571-8583.
5. Chen S, Xu Y, Yuan X, Bubley GJ, Balk SP (2006). Androgen receptor phosphorylation and stabilization in prostate cancer by cyclin-dependent kinase 1. Proc Natl Acad Sci USA 103, 15969-15974.
6. Cheung ZH, Ip NY (2012). Cdk5: a multifaceted kinase in neurodegenerative diseases. Trends Cell Biol 22, 169-175.
7. Choi JH, Banks AS, Estall JL, Kajimura S, Boström P, Laznik D, Ruas JL, Chalmers MJ, Kamenecka TM, Blüher M, et al. (2010). Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5. Nature 466, 451-456.
8. Daval M, Gurlo T, Costes S, Huang C-J, Butler PC (2011). Cyclin-dependent kinase 5 promotes pancreatic β-cell survival via Fak-Akt signaling pathways. Diabetes 60, 1186-1197.
9. Demelash A, Rudrabhatla P, Pant HC, Wang X, Amin ND, McWhite CD, Naizhen X, Linnoila RI (2012). Achaete-scute homologue-1 (ASH1) stimulates migration of lung cancer cells through Cdk5/p35 pathway. Mol Biol Cell 23, 2856-2866.
10. Eastham JA, Stapleton AM, Gousse AE, Timme TL, Yang G, Slawin KM, Wheeler TM, Scardino PT, Thompson TC (1995). Association of p53 mutations with metastatic prostate cancer. Clin Cancer Res 1, 1111-1118.
11. Eggers JP, Grandgenett PM, Collisson EC, Lewallen ME, Tremayne J, Singh PK, Swanson BJ, Andersen JM, Caffrey TC, High RR, et al. (2011). Cyclin-dependent kinase 5 is amplified and over expressed in pancreatic cancer and activated by mutant K-Ras. Clin Cancer Res 17, 6140-6150.
12. Gordon V, Bhadel S, Wunderlich W, Zhang J, Ficarro SB, Mollah SA, Shabanowitz J, Hunt DF, Xenarios I, Hahn WC, et al. (2010). CDK9 regulates AR promoter selectivity and cell growth through serine 81 phosphorylation. Mol Endocrinol 24, 2267-2280.
13. Ha S, Ruoff R, Kahoud N, Franke TF, Logan SK (2011). Androgen receptor levels are upregulated by Akt in prostate cancer. Endocr Relat Cancer 18, 245-255.
14. Hamdane M, Bretteville A, Sambo A-V, Schindowski K, Bégard S, Delacourte A, Bertrand P, Buée L (2005). p25/Cdk5-mediated retinoblastoma phosphorylation is an early event in neuronal cell death. J Cell Sci 118, 1291-1298.
15. Higuchi M, Onishi K, Kikuchi C, Gotoh Y (2008). Scaffolding function of PAK in the PDK1-Akt pathway. Nat Cell Biol 10, 1356-1364.
16. Hsu F-N, Chen M-C, Chiang M-C, Lin E, Lee Y-T, Huang P-H, Lee G-S, Lin H (2011). Regulation of androgen receptor and prostate cancer growth by cyclin-dependent kinase 5. J Biol Chem 286, 33141-33149.
17. Imanishi SY, Kochin V, Ferraris SE, de Thonel A, Pallari H-M, Corthals GL, Eriksson JE (2007). Reference-facilitated phosphoproteomics: fast and reliable phosphopeptide validation by microLC-ESI-Q-TOF MS/MS. Mol Cell Proteomics 6, 1380-1391.
18. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ (2003). Cancer statistics, 2003. CA Cancer J Clin 53, 5-26.
19. Jiang X, Chen S, Asara JM, Balk SP (2010). Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits. J Biol Chem 285, 14980-14989.
20. Kino T, Ichijo T, Amin ND, Kesavapany S, Wang Y, Kim N, Rao S, Player A, Zheng Y-L, Garabedian MJ, et al. (2007). Cyclin-dependent kinase 5 differentially regulates the transcriptional activity of the glucocorticoid receptor through phosphorylation: clinical implications for the nervous system response to glucocorticoids and stress. Mol Endocrinol 21, 1552-1568.
21. Kreisberg JI, Malik SN, Prihoda TJ, Bedolla RG, Troyer DA, Kreisberg S, Ghosh PM (2004). Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res 64, 5232-5236.
22. Levacque Z, Rosales JL, Lee K-Y (2012). Level of cdk5 expression predicts the survival of relapsed multiple myeloma patients. Cell Cycle 11, 4093-4095.
23. Li B-S, Ma W, Jaffe H, Zheng Y, Takahashi S, Zhang L, Kulkarni AB, Pant HC (2003). Cyclin-dependent kinase-5 is involved in neuregulin-dependent activation of phosphatidylinositol 3-kinase and Akt activity mediating neuronal survival. J Biol Chem 278, 35702-35709.
24. Liang Q, Li L, Zhang J, Lei Y, Wang L, Liu D-X, Feng J, Hou P, Yao R, Zhang Y, et al. (2013). CDK5 is essential for TGF-β1-induced epithelial-mesenchymal transition and breast cancer progression. Sci Rep 3, 2932.
25. Liebl J, Fürst R, Vollmar AM, Zahler S (2011). Twice switched at birth: cell cycle-independent roles of the "neuron-specific" cyclin-dependent kinase 5 (Cdk5) in non-neuronal cells. Cell Signal 23, 1698-1707.
26. Lin H, Juang J-L, Wang PS (2004). Involvement of Cdk5/p25 in digoxin-triggered prostate cancer cell apoptosis. J Biol Chem 279, 29302-29307.
27. Liu R, Tian B, Gearing M, Hunter S, Ye K, Mao Z (2008). Cdk5-mediated regulation of the PIKE-A-Akt pathway and glioblastoma cell invasion. Proc Natl Acad Sci USA 105, 7570-7575.
28. Morgan TM, Koreckij TD, Corey E (2009). Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway. Curr Cancer Drug Targets 9, 237-249.
29. Nagano T, Hashimoto T, Nakashima A, Hisanaga S, Kikkawa U, Kamada S (2013). Cyclin I is involved in the regulation of cell cycle progression. Cell Cycle 12, 2617-2624.
30. Pallari H-M, Lindqvist J, Torvaldson E, Ferraris SE, He T, Sahlgren C, Eriksson JE (2011). Nestin as a regulator of Cdk5 in differentiating myoblasts. Mol Biol Cell 22, 1539-1549.
31. Pareek TK, Lam E, Zheng X, Askew D, Kulkarni AB, Chance MR, Huang AY, Cooke KR, Letterio JJ (2010). Cyclin-dependent kinase 5 activity is required for T cell activation and induction of experimental autoimmune encephalomyelitis. J Exp Med 207, 2507-2519.
32. Peuhu E, Rivero-Müller A, Stykki H, Torvaldson E, Holmbom T, Eklund P, Unkila M, Sjöholm R, Eriksson JE (2010). Inhibition of Akt signaling by the lignan matairesinol sensitizes prostate cancer cells to TRAIL-induced apoptosis. Oncogene 29, 898-908.
33. Rytinki M, Kaikkonen S, Sutinen P, Paakinaho V, Rahkama V, Palvimo JJ (2012). Dynamic SUMOylation is linked to the activity cycles of androgen receptor in the cell nucleus. Mol Cell Biol 32, 4195-4205.
34. Sahlgren CM, Mikhailov A, Vaittinen S, Pallari H-M, Kalimo H, Pant HC, Eriksson JE (2003). Cdk5 regulates the organization of Nestin and its association with p35. Mol Cell Biol 23, 5090-5106.
35. Strock CJ, Park J-I, Nakakura EK, Bova GS, Isaacs JT, Ball DW, Nelkin BD (2006). Cyclin-dependent kinase 5 activity controls cell motility and metastatic potential of prostate cancer cells. Cancer Res 66, 7509-7515.
36. Sutinen P, Malinen M, Heikkinen S, Palvimo JJ (2014). SUMOylation modulates the transcriptional activity of androgen receptor in a target gene and pathway selective manner. Nucleic Acids Res 42, 8310-8319.
37. Taplin ME, Bubley GJ, Ko YJ, Small EJ, Upton M, Rajeshkumar B, Balk SP (1999). Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 59, 2511-2515.
38. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, et al. (2010). Integrative genomic profiling of human prostate cancer. Cancer Cell 18, 11-22.
39. Thomas C, Lamoureux F, Crafter C, Davies BR, Beraldi E, Fazli L, Kim S, Thaper D, Gleave ME, Zoubeidi A (2013). Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo. Mol Cancer Ther 12, 2342-2355.
40. Whang YE, Wu X, Suzuki H, Reiter RE, Tran C, Vessella RL, Said JW, Isaacs WB, Sawyers CL (1998). Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci USA 95, 5246-5250.
41. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinänen R, Palmberg C, Palotie A, Tammela T, Isola J, Kallioniemi OP (1995). In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 9, 401-406.
42. Xin L, Teitell MA, Lawson DA, Kwon A, Mellinghoff IK, Witte ON (2006). Progression of prostate cancer by synergy of AKT with genotropic and nongenotropic actions of the androgen receptor. Proc Natl Acad Sci USA 103, 7789-7794.
43. Yoshimoto M, Cutz J-C, Nuin PAS, Joshua AM, Bayani J, Evans AJ, Zielenska M, Squire JA (2006). Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias. Cancer Genet Cytogenet 169, 128-137.
44. Zhang J, Li H, Yabut O, Fitzpatrick H, D'Arcangelo G, Herrup K (2010). Cdk5 suppresses the neuronal cell cycle by disrupting the E2F1-DP1 complex. J Neurosci 30, 5219-5228.
45. Zhang J, Li H, Zhou T, Zhou J, Herrup K (2012). Cdk5 levels oscillate during the neuronal cell cycle: Cdh1 ubiquitination triggers proteosome-dependent degradation during S-phase. J Biol Chem 287, 25985-25994.
46. Zhou BP, Liao Y, Xia W, Zou Y, Spohn B, Hung MC (2001). HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol 3, 973-982.
47. Zong H, Chi Y, Wang Y, Yang Y, Zhang L, Chen H, Jiang J, Li Z, Hong Y, Wang H, et al. (2007). Cyclin D3/CDK11p58 complex is involved in the repression of androgen receptor. Mol Cell Biol 27, 7125-7142.